Multiply Labs used cobots to ship breakthrough leads to the manufacturing of cell therapies. Supply: Common Robots
Precision medication, during which advanced remedies for most cancers and different circumstances are customized, is often expensive, limiting affected person entry to care. Multiply Labs Inc. has developed a “robotic biomanufacturing cluster” that it stated can scale back the price of life-saving cell therapies by 74%.
“Traditionally, cell and gene remedy manufacturing has been guide, virtually artisanal,” stated Fred Parietti, CEO of Multiply Labs. “Knowledgeable scientists carry out a whole lot of duties by hand, from pipetting to shaking cells.”
San Francisco-based Multiply Labs has developed cloud-controlled automated methods for the manufacturing of individualized medication at scale. Its crew consists of mechanical engineers, electrical engineers, pc scientists, software program engineers, and pharmaceutical scientists.
The firm stated its clients embrace a few of largest world organizations within the superior pharmaceutical manufacturing house.
Personalized therapies want exact manufacturing
Customized cell therapies are sometimes used to deal with blood cancers resembling lymphoma and leukemia. In contrast to mass-produced medication, they require a personalized dose from every affected person’s personal cells, making large-batch manufacturing unimaginable. Such therapies are at the moment priced between $300,000 and $2 million per dose.
As well as, a single microbial contamination can render the complete product unusable, resulting in expensive manufacturing failures.
Multiply Labs selected Common Robots A/S (UR) for its modular biomanufacturing cluster after carefully evaluating a number of completely different collaborative robotic arms.
“UR was chosen resulting from their essential six-axis capabilities, unequalled power mode for delicate dealing with, seamless software program integration, sturdy group assist, and cleanroom compatibility,” stated Nadia Kreciglowa, head of robotics at Multiply Labs.
Editor’s be aware: RoboBusiness 2025, which might be on Oct. 15 and 16 in Santa Clara, Calif., will embrace tracks on bodily AI, enabling applied sciences, and design and growth finest practices. It will likely be co-located with medical machine occasion DeviceTalks West, and registration is now open.
UR cobots can replicate intricate processes
As revealed in peer-reviewed research with the College of California, San Francisco (UCSF), Multiply Labs used a number of UR cobots working in parallel, stacked ground to ceiling with collision avoidance, to deal with the complete cell remedy manufacturing course of.
The brand new partnership, Common Robots’ first within the cell and gene remedy sector, illustrates the good potential of collaborative robots in healthcare, based on Jean-Pierre Hathout, president of Odense, Denmark-based UR, a Teradyne firm.
“By empowering Multiply Labs to copy intricate guide processes with excessive precision and scale, our cobots are redefining effectivity in pharmaceutical manufacturing,” he acknowledged. “Extra importantly, it’s driving vital price reductions whereas broadening entry to life-saving remedies. At its core, this partnership is a testomony to how robotics can elevate human functionality and serve crucial wants in medication.”
Multiply Labs makes use of imitation studying for course of constancy
Multiply Labs cited its imitation studying expertise as enabling robots be taught from skilled human demonstrations relatively than dictating new processes.
“We ask the pharmaceutical firms that we work with to videotape their scientists performing the duties,” defined Parietti. “We then feed this information to the robots, and the robots be taught to successfully replicate what scientists have been doing within the lab, simply extra effectively, extra repeatably, 24/7, and in parallel.”
He added that this strategy permits the UR cobots to “self-learn a whole lot of latest duties” with exponentially decrease engineering prices.
Multiply Labs’ system faithfully replicates guide processes with enhanced effectivity, repeatability, and sanitary circumstances, based on the companions. This course of constancy can be essential for regulatory compliance, doubtlessly saving a long time and billions of {dollars} in re-approval prices by replicating current, already permitted processes, stated Dr. Jonathan Esensten, director of the Superior Biotherapy Middle at Sheba Medical Middle.
“As an alternative of ranging from sq. zero when it comes to drug approval, firms can now doc that that is the very same manufacturing course of. It simply occurs to be finished by a robotic.” he famous. Dr. Esensten, a former member of the UCSF school, labored with Multiply Labs to develop the system.
Multiply Labs makes use of imitation studying to coach robots tips on how to do new duties. Supply: Common Robots
Multiply Labs reduces prices, house utilization, contamination
“Once we in contrast a conventional guide manufacturing course of for these cell therapies to a robotic course of doing the very same course of, we discovered a price discount of roughly 74%,” stated Esensten. “Rising T cells is one thing that we’ve been doing for a very long time, however to have the robotic system do it with none human palms touching the cells all through the method, that could be a quantum leap when it comes to having the ability to manufacture these medicines at a decrease price and in a smaller house.”
Along with price financial savings, the robotic system can drastically enhance house utilization, Parietti stated. It might probably unlock sufficient house to retailer as much as 100x extra affected person doses per sq. foot of cleanroom in contrast with a typical guide course of. High quality and sterility are additionally considerably enhanced, he stated.
“Robots don’t breathe, they usually don’t contact stuff they’re not supposed to the touch,” noticed the Multiply Labs CEO.
“Whereas human dealing with led to contamination in a single case, we didn’t see any contamination within the robotic course of,” stated Dr. Esensten in reference to the UCSF research.
The Multiply Labs robotic cluster is already deployed at world pharmaceutical firms with outcomes now additionally documented in collaboration with scientists at Stanford College.
“It will actually change the best way we take into consideration the manufacturing of those bespoke, customized cell and gene therapies for sufferers,” stated Parietti. “We are going to in the end enhance affected person entry globally by reducing manufacturing prices, enabling distributed manufacturing worldwide of those life-saving therapies.”
